Comparative Pharmacology
Head-to-head clinical analysis: OXY KESSO TETRA versus OXYTETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXY KESSO TETRA versus OXYTETRACYCLINE HYDROCHLORIDE.
OXY-KESSO-TETRA vs OXYTETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Oxycodone is combined with aspirin (OXY-KESSO-TETRA) for analgesic synergy.
Oxytetracycline binds reversibly to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
200 mg orally every 8 hours for 10 days.
250-500 mg orally every 6 hours or 1-2 g/day divided every 12 hours intravenously.
None Documented
None Documented
Terminal elimination half-life approximately 8-12 hours in adults with normal renal function; prolonged to 20-40 hours in moderate to severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
6-10 hours (prolonged to 48-100 hours in renal impairment; consider dose adjustment in CrCl <50 mL/min)
Primarily renal (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 20-30% is metabolized hepatically with metabolites excreted renally; less than 5% eliminated via bile/feces.
Renal (60-70% unchanged by glomerular filtration); biliary/fecal (20-35%)
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic